Candriam S.C.A. Lowers Stake in Moderna, Inc. $MRNA

Candriam S.C.A. lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 54.0% in the first quarter, HoldingsChannel.com reports. The firm owned 281,946 shares of the company’s stock after selling 330,916 shares during the period. Candriam S.C.A.’s holdings in Moderna were worth $7,993,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MRNA. Voloridge Investment Management LLC boosted its position in Moderna by 335.6% in the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after buying an additional 1,996,003 shares during the period. Invesco Ltd. boosted its position in Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after buying an additional 877,162 shares during the period. Nuveen LLC purchased a new position in Moderna in the 1st quarter valued at approximately $19,510,000. Deutsche Bank AG boosted its position in Moderna by 54.7% in the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company’s stock valued at $78,756,000 after buying an additional 669,614 shares during the period. Finally, TB Alternative Assets Ltd. purchased a new position in Moderna in the 1st quarter valued at approximately $18,495,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $26.22 on Friday. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $86.80. The firm has a market capitalization of $10.20 billion, a P/E ratio of -3.48 and a beta of 1.83. The company’s fifty day moving average price is $29.17 and its 200 day moving average price is $29.17.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna’s quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

MRNA has been the subject of several recent research reports. Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They issued a “hold” rating for the company. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Citigroup initiated coverage on shares of Moderna in a research report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price target for the company. Morgan Stanley reissued an “equal weight” rating and issued a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Finally, Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $43.59.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.